People
Since COVID-19 began its sweep across the United States, data has shown the disease caused by the novel coronavirus has disproportionately impacted racial and ethnic minority groups across the country.
Questions over the efficacy and safety of hydroxychloroquine continue to be raised following the World Health Organization’s decision to temporarily halt a study of the malaria drug as a potential treatment for COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
A hot, humid summer will slow coronavirus transmission but, on its own isn’t likely to end the COVID-19 pandemic, according to a new study.
The collaboration, announced Wednesday, aims to make disposable, hand-held diagnostics that are as accurate as lab tests and as easy to use as home pregnancy kits.
The study found that of the 15,000 patients who received either of the drugs were almost twice as likely to die compared to the patients who did not receive them. The research was published in the journal The Lancet.
To learn more about ImmunityBio’s HIV drug candidate, BioSpace spoke to Dr. Whitney and Jeffrey Safrit, PhD, director of Cell-Mediated Therapies in Virology at NantKwest.
Pharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Henry Li, Sorrento’s co-founder, director, president and chief executive officer, did a follow-up interview with BioSpace to discuss the news and speculation surrounding it.
The hopes of billions of people are riding on at least one of the vaccine candidates for COVID-19 currently in clinical development becoming a commercialized preventative treatment for the world. While hopes are high, caution is still being urged by drugmakers and epidemiologists.
PRESS RELEASES
